Clinical impact of implementation of rapid diagnostic testing of blood cultures with Staphylococcus aureus on patient outcomes

Diagn Microbiol Infect Dis. 2021 Nov;101(3):115474. doi: 10.1016/j.diagmicrobio.2021.115474. Epub 2021 Jul 1.

Abstract

Rapid diagnostic testing in microbiology labs shortens the time to identification of bacteria in blood cultures. Cepheid® GeneXpert® MRSA/SA PCR can be used to distinguish MRSA and MSSA from non-Staphylococcus aureus organisms in blood cultures. This study aims to determine if implementation of MRSA/SA PCR for blood culture pathogen identification, plus daily antimicrobial stewardship intervention, can reduce time to appropriate therapy, vancomycin duration, 30 day mortality, and 90 day recurrence in veterans. A total of 113 patients in the pre-implementation cohort and 73 patients in the post-implementation cohort were evaluated. Time to appropriate therapy was decreased from 49.8 (pre-implementation) to 20.6 (post-implementation) hours. There was a numerically shorter median duration of vancomycin therapy in the post-implementation group. There was no difference in 30 day mortality or 90 day recurrence between groups. Use of MRSA/SA PCR can improve antimicrobial use when combined with once-daily antimicrobial stewardship review.

Keywords: Bacteremia; Blood culture; Bloodstream infection; Cepheid®; Rapid Diagnostic Testing (RDT); Staphylococcus aureus.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Stewardship / methods
  • Bacteremia / diagnosis*
  • Blood Culture / methods*
  • Health Plan Implementation / methods*
  • Humans
  • Retrospective Studies
  • Staphylococcal Infections / blood*
  • Staphylococcal Infections / diagnosis*
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / mortality
  • Staphylococcus aureus / genetics*
  • Staphylococcus aureus / isolation & purification
  • Time Factors

Substances

  • Anti-Bacterial Agents